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Abstract
The aim of this document is to provide general guidance and specific recommendations on the practice of
cardiovascular magnetic resonance (CMR) in the era of the COVID-19 pandemic. There are two major
considerations. First, continued urgent and semi-urgent care for the patients who have no known active COVID-19
should be provided in a safe manner for both patients and staff. Second, when necessary, CMR on patients with
confirmed or suspected active COVID-19 should focus on the specific clinical question with an emphasis on
myocardial function and tissue characterization while optimizing patient and staff safety.
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Introduction
COVID-19 is the clinical syndrome resulting from infec-
tion with a novel coronavirus, the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), which was first
identified in December 2019. SARS-CoV-2 has since
spread across the world [1, 2]. Declared a pandemic by the
World Health Organization, there are over 1.3 million
confirmed cases of COVID-19 worldwide in 185 countries
and more than 178,000 associated deaths, as of April 22nd,
2020 [3].
As the COVID-19 pandemic propagates worldwide,
there is an increasing resource burden on healthcare
systems, and escalated measures are necessary to protect
patients and healthcare workers from infection. At the
same time, care for patients with cardiovascular disease
and without active COVID-19 needs to continue during
these circumstances, albeit with modifications. In the
setting of the COVID-19 pandemic, approaches to diag-
nostic testing, including cardiovascular magnetic reson-
ance (CMR), need to be adapted to allow for safe practices
for urgent and semi-urgent CMR studies and appropriate
deferral of elective exams. Furthermore, many patients
with confirmed active COVID-19 have underlying cardio-
vascular disease or present with ischemic or inflammatory
cardiac injury, such that an indication for CMR may arise.
CMR is the reference non-invasive standard for cardiac
function and tissue characterization and may offer an ef-
fective and efficient diagnostic imaging choice to obtain
critical information for clinical decision-making.
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Purpose
The aim of this document is to provide general guidance
and specific recommendations on the practice of CMR
in the era of the COVID-19 pandemic. Recognizing that
practice patterns and policies vary depending on institu-
tion and locale, these recommendations are not meant
to be restrictive but rather to serve as a general frame-
work. As the situation is rapidly evolving, recommenda-
tions will be updated continuously and provided online
in the SCMR’s COVID-19 Preparedness Toolkit https://
scmr.org/page/COVID19 [4]. The recommendations are
summarized in Fig. 1.
CMR for patients without active COVID-19
Modifications to routine CMR operations
In the setting of the COVID-19 pandemic, measures of
physical distancing have universally been employed to
diminish community transmission of the disease. For
healthcare facilities, the need to minimize the exposure
of patients and healthcare staff has prompted the United
States Centers for Disease Control and Prevention
(CDC), United Kingdom Public Health England (PHE),
and other national health authorities to advise resched-
uling non-urgent outpatient visits [5]. Determination of
what constitutes a “non-urgent” CMR exam may be un-
clear due to its dependence on many unknown variables
such as the status of the pandemic in the local area, the
relevance and urgency of the study for clinical decision-
making, and constraints of the healthcare facility (clinic
or hospital). Whereas deferral of most non-urgent exams
is appropriate, the CDC also acknowledges the need to
“consider accelerating the timing of high priority screen-
ing and intervention needs for the short-term, in
Fig. 1 Recommendations for CMR during the COVID-19 Pandemic
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anticipation of the possible need to manage an influx of
COVID-19 patients in the weeks to come” [6].
Therefore, the triaging of routine CMR exams may be
essential to maintain safe and efficient laboratory oper-
ations. A thorough evaluation of the clinical indication
for each CMR request is warranted, and appropriate
use criteria for imaging [7] should be rigorously ap-
plied. In situations where, multiple imaging modalities
may be appropriate, testing should be streamlined to
reduce redundancy while optimizing diagnostic value
for immediate clinical decision making. While most
CMR practitioners are multimodality imagers, consult-
ation with other imaging colleagues or clinicians may
be necessary, depending on their level of expertise. Another
consideration is the higher exposure risk of other imaging
modalities (e.g. aerosolization risk of transesophageal echo-
cardiography) or diagnostic procedures (e.g. invasive angi-
ography), which may lead to increased CMR referrals.
Table 1 provides suggested timelines for common CMR
indications to aid in judicious timing of necessary exams.
However, cases should be evaluated on an individual basis,
and direct communication between referring physicians
and CMR practitioners is essential. Clinical judgment with
regard to the patient’s condition throughout the duration of
the pandemic must be balanced with the associated expos-
ure risk with CMR imaging during the pandemic. Risks and
benefits of imaging timing should be discussed with pa-
tients to achieve shared decision-making, particularly for
Table 1 Suggested timeline for CMR exams by expert consensus based on common clinical indications (not intended to be
exhaustive and individual clinical circumstances need to be considered)
Elective (wait 2–4 months) Semi-urgent (1 week – 2 months) Urgent (< 1 week)
Cardiomyopathy Suspected hypertrophic cardiomyopathy
or follow-up for late gadolinium
enhancement
Family history of sudden death,
arrhythmogenic cardiomyopathy, or
other screening in clinically stable and
asymptomatic patients
Suspected dilated cardiomyopathy to
assess LV function and etiology
Suspected infiltrative cardiomyopathy,
depending on impact on treatment
Follow-up of iron overload pending
chelation therapy
Family history of sudden death,
arrhythmogenic cardiomyopathy, or
other screening in symptomatic
patients
Acute myocarditis with implications
for immediate management
(within 1–3 days)
Ischemic heart
disease
Stress perfusion in stable ischemic heart
disease
Viability for non-urgent revascularization
Stress perfusion in newly
symptomatic patients
Viability for revascularization in
patients with recent symptoms
Ischemia and viability to guide
urgent revascularization
Masses Suspected benign mass, unlikely to
prompt urgent surgery or biopsy
Question of thrombus with
non-diagnostic echo and no
contraindication to empiric
anticoagulation
Suspected malignancy, likely to
prompt imminent surgery, biopsy,
or chemotherapy
Suspected intracardiac mass or
thrombus with contraindication
to anticoagulation or in patients
with suspected embolic events
Congenital
heart disease
Follow-up of right ventricular function
and pulmonary regurgitation in a
clinically stable patient
Pre-interventional planning in a
symptomatic patient
Information that can only be
derived from CMR is needed for
decision-making in an acutely
ill patient
Arrhythmia Ablation planning for atrial fibrillation
in clinically stable patients
Ablation planning for ventricular
arrhythmias in clinically stable
patients
Planning for urgent ablation in
unstable patients
Valvular disease Follow up exams in aortic valve
stenosis, or quantification of aortic,
mitral, tricuspid or pulmonic regurgitation in clinically stable
patients
Transcatheter aortic valve
replacement (TAVR) planning
pending procedural urgency
TAVR, aortic, mitral, tricuspid, or pulmonic
regurgitation quantification, urgent
surgery or percutaneous therapy
planned
Pericardial
disease
Follow-up for pericarditis in
asymptomatic and stable patients
Acute pericarditis evaluation
leading to potential change in
management in symptomatic
patients
Pericardial constriction requiring
potential urgent surgery
Pulmonary
hypertension
Evaluate right ventricular function
for escalation of therapy in clinically
stable patients
Evaluate right ventricular function
for escalation of therapy in
symptomatic patients
Aortic disease Follow up dissection and/or
aneurysms or repair/coarctation in
stable patients
Monitoring of near intervention
threshold aneurysms/coarctation
Suspected acute dissection
(immediately)
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patients at high risk of complications related to potential
SARS-CoV-2 infection (e.g., immunocompromised, older
age, and advanced cardiopulmonary disease). CMR, if pri-
marily used for guidance of a scheduled or potential surgi-
cal or percutaneous intervention, should be scheduled
according to the projected timing of the intervention. Dur-
ing the pandemic, constraints on hospital resources may
affect the availability of elective procedural or surgical
services.
For inpatient referrals, similar considerations and ap-
proaches to triaging should be undertaken. Under nor-
mal conditions, elective CMR studies may be performed
for convenience while the patient is hospitalized. How-
ever, in the setting of the COVID-19 pandemic, expos-
ure risks may outweigh the benefit of completing an
elective CMR as an inpatient. If feasible, such CMR
studies should be deferred to the outpatient setting and
postponed until recovery from the acute illness that led
to hospitalization, unless the CMR findings are likely to
impact acute or near-term management.
Provisions for triaging and determining the optimal
timing of CMR studies could temporarily alter the rou-
tine scheduling workflow. Clear strategies for handling
these workflow changes during the COVID-19 pandemic
should be developed and communicated amongst the
CMR physicians, technologists, and referring providers.
Awareness of systematic changes should also be raised
on a departmental or institutional level. Clear channels
of communication with CMR physicians must also be
maintained to provide optimal consultation services to
referring physicians.
Safety precautions and procedures
Precautions for preventing SARS-CoV-2 contamination
of the CMR laboratory should be implemented in all as-
pects of the imaging process, from patient preparation
to image acquisition and interpretation. All patients
should be screened prior to arrival by phone for symp-
toms of and risk factors for COVID-19. Rules of physical
distancing in waiting areas and common workspaces
(e.g., control room and reading room) and universal pre-
cautions, such as hand hygiene and limiting close patient
contact, should be implemented. Minimizing patient
time in the waiting area also needs to be accounted for
regarding scheduling. When physical distancing is not
possible, such as during patient preparation, a universal
mask policy may be protective. All patients should wear
a surgical mask (with removal of the nasal metal band
and adhesive tape used across the bridge of the nose) for
the entire visit to the imaging facility. Proper use of add-
itional personal protective equipment (PPE) by
personnel involved in patient preparation and scanning,
such as eye shields, head caps, gowns, shoe covering and
gloves, as deemed appropriate by institutional infection
control policy, is also essential [8]. Prevention of trans-
mission of SARS-CoV-2 by asymptomatic individuals is
paramount. Other recommendations for PPE per patient
encounter may vary depending on the likelihood of
SARS-CoV-2 infection. Specific precautions and issues
regarding patients with confirmed active or sus-
pected COVID-19 patients are addressed in a subse-
quent section. Remote image processing and
interpretation solutions should be implemented using
workstations outside of common reading rooms. For de-
tailed guidance on how to manage suspected or con-
firmed active COVID-19 patients in the CMR suite,
please consult the SCMR’s COVID-19 Preparedness
Toolkit https://scmr.org/page/COVID19 [4].
Healthcare and office staffing should be reduced to the
minimum necessary to support CMR operations and
thereby dissuade congregating in common areas. It
should be emphasized that all staff self-monitor for
symptoms and abstain from entering the workplace if
symptomatic. Technologist and physician coverage
should be arranged to allow for balanced rotation of
personnel and consideration of the safety of staff mem-
bers with underlying conditions that pose a higher risk
of complications from infection. Depending on the bur-
den of the pandemic, some imaging physicians and
nurses may be quarantined or deployed to other aspects
of patient care, and contingency plans for coverage may
be needed. In academic institutions, the number of on-
site trainees may be limited to ensure physical distancing
and reduce unnecessary exposure. Trainee education
should continue through remote learning platforms.
In terms of environmental services, appropriate clean-
ing and decontamination of the scanner room and pa-
tient holding area should be performed according to
institutional policy. Scheduling should allocate sufficient
time between exams to allow for thorough cleaning of
CMR equipment surfaces and patient monitoring devices
by staff wearing PPE (surgical mask and gloves in the ab-
sence of known active COVID-19). Similarly, worksta-
tions, desktops, phones, and door handles, etc. should be
cleaned routinely between operators. Sufficient time
should be allotted for surfaces to dry after disinfection.
CMR protocols
In the course of triaging CMR requests, it is especially im-
portant that imaging physicians are sufficiently familiar with
the clinical context and well-equipped to protocol exams
appropriately. Shorter scan protocols leave more time for
donning/doffing of PPE and for CMR table/room cleaning
between scans. The risks of a more comprehensive exam
(and thus increased exposure) must be weighed against the
benefits of a more tailored exam based on the clinical ques-
tion. These recommendations for CMR differ from those of
echocardiography, in which an operator remains in close
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proximity to the patient for the duration of the exam [9].
Standard clinical protocols for the laboratory, in accordance
with the SCMR recommendations [10] should generally be
utilized, and rapid acquisition protocols are encouraged
when appropriate. Contrast-enhanced CMR imaging can
reduce the need for repeat imaging or additional tests that
may further expose the patient or other healthcare workers
to infection, and may offset the potential exposure risk to
those obtaining intravenous access for gadolinium-based
contrast agent administration. However, urgent exams are
typically performed on inpatients, most of whom will
already have an intravenous line. Therefore, standard CMR
protocols tailored to the specific indication should generally
be performed, and greater emphasis should be placed on
selecting the appropriate protocol for each case.
CMR in ventilated patients
CMR can be performed on ventilated patients under
specific conditions, although this is generally discour-
aged unless there is a strong clinical indication, espe-
cially in the COVID-19 era (see below for scanning in
confirmed or suspected active COVID-19 patient). An
MRI conditional or compatible ventilator must be used.
Please consult ventilator manufacturer specifications (for
MRI compatibility of equipment, visit MRIsafety.com).
In general, the CMR compatible ventilator equipment
should be positioned outside the scan room 200 Gauss
line and can be tethered to the wall for added safety.
The patient needs to be transferred from the intensive
care unit to the CMR unit accompanied by a respiratory
therapist. Specific protocols for performing CMR scans
in ventilated patients is beyond the scope of this docu-
ment and institutional policy should be followed.
CMR for confirmed active COVID-19 and patients under
investigation
Indications
Acute myocardial injury has been frequently reported in
COVID-19 patients and is associated with high mortality
[10–12]. Acute myocarditis in COVID-19 may present
as a fulminant process, and may respond to immunosup-
pressive therapy [13]. One case report documents the
results of a CMR scan in a COVID-19 patient with sus-
pected myocarditis [14]. Diffuse ST elevation, as well as
elevated high-sensitive cardiac troponin T and N-
terminal-pro brain natriuretic peptide levels, were found
in a patient with no pre-existing cardiovascular risk fac-
tors who presented with one week of severe fatigue,
fever, and dry cough. CMR demonstrated high T2-signal
and possible diffuse late gadolinium enhancement (LGE).
In patients who have troponin elevation, it is important to
differentiate among possible etiologies including: acute
coronary syndrome, demand ischemia, myocarditis, and
acute myocardial injury in disseminated intravascular
coagulation/cytokine storm/multisystem failure. The pa-
tient in the latter situation may be critically ill and may
not be a candidate for CMR, but in many other clinical
scenarios, CMR can be an important tool to differentiate
types of myocardial injury.
CMR must be undertaken using a holistic approach,
and weighed against other diagnostic modalities in terms
of risk to the patient and healthcare personnel. If an im-
aging test does not have a significant impact on clinical
decision-making, it should not be performed. However,
if an imaging test is deemed necessary, a single imaging
test should be the goal, whether or not it is computed
tomography (CT), echocardiography, nuclear imaging, or
CMR. CMR appears most appropriate in patients with
clinically suspected acute myocardial injury, as defined
by clinical criteria (symptoms, ECG abnormalities) and
serologic evidence of cardiomyocyte damage with tropo-
nin elevation. In these patients, if unable to differentiate
based on other clinical findings, CMR can differentiate
between ischemic and non-ischemic etiologies, and fur-
ther demonstrate the extent and severity of the injury
and its impact on ventricular function. Quantitative car-
diac output assessment can be helpful in differentiating
high-output failure (caused by septic physiology) from
low-output states (primarily caused by a reduced ven-
tricular stroke volume). We recommend consulting with
a multimodality imaging expert on the ideal testing mo-
dality to answer the diagnostic question and to reduce
the risk of exposure. If not required for immediate clin-
ical decision-making, CMR should be deferred until the
COVID-19 patient has fully recovered and is no longer
infectious.
Operational procedures
In patients with a high likelihood of or confirmed active
COVID-19, CMR should be performed with adequate
droplet and aerosol precautions for the staff members,
i.e., N95/PPF2–3 respirator, eye shield (visor), gown, and
gloves. If feasible, dedicating a single CMR scanner for
COVID-19 patients would be ideal. The CMR suite
should be treated as a highly contaminated area, because
SARS-CoV-2 can survive on some surfaces for up to sev-
eral days, although less likely to still be infectious [15]. If
the CMR control room can be closed off as a separate
area, it is best to be kept as a clean area free from any
staff members who have had patient contact. The best
practice would include one technologist in PPE to carry
out the necessary tasks in the scanning room, and a sec-
ond technologist to be confined to the control room for
immediate scanning once the patient is positioned in the
scanner. If the patient is intubated, precautions with
regards to respiratory care will have to be instituted (see
specific section below). Interpreting pulmonary findings
should be performed collaboratively with chest radiology
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physicians if the CMR imager is not a radiologist, and
reported in a similar fashion according to recently pub-
lished guidelines for chest CT [16]. In patients with de-
creased renal function, macrocyclic gadolinium-based
contrast agents should be used with caution in patients
with an estimated glomerular filtration rate (eGFR) of <
30ml/min/1.73m2. Acute kidney injury was reported in
5.1% of patients with COVID-19, and CMR exams requir-
ing gadolinium contrast should be delayed until eGFR is
> 30ml/min/1.73m2 [17]. If the patient has difficulty
with breath-holding, real-time cine sequences and free-
breathing LGE sequences should be utilized whenever
possible. The focus of the exam should be on findings that
would impact management, such as myocardial function,
as well as tissue characterization with T1, T2, and LGE
imaging.
CMR in ventilated confirmed or suspected active COVID-19
patients
CMR in ventilated patients with confirmed or suspected ac-
tive COVID-19 represents a particular challenge. The con-
ventional (non-MRI conditional) ventilator equipment
needs to be disconnected in a specific separate negative
pressure room outside but near the CMR scan room. All
personnel accompanying and interacting directly with the
patient must wear PPE (minimally N95 mask, eye shield ,
gown, cap, shoe covering, and gloves). The patient is then
connected to the CMR compatible ventilator and both are
moved into the scan room. Similar precautions (i.e., nega-
tive pressure room, PPE) need to be used when moving the
patient from the scan room/MRI conditional ventilator to a
conventional ventilator. Institutional policy regarding spe-
cific details about performing CMR scans on ventilated pa-
tients should be followed. The CMR protocol for ventilated
patients should consist of rapid real-time free breathing im-
aging sequences.
Conclusion
In the era of the COVID-19 pandemic, as CMR pro-
viders, we must work closely with referring physicians to
continue to provide care to patients without known ac-
tive COVID-19 who need urgent and semi-urgent CMR
imaging for diagnosis and pre-procedural planning.
Standard or rapid protocols should be employed for
these patients according to the indication. In patients
with confirmed or suspected active COVID-19 and clin-
ical evidence of myocardial injury, CMR may provide
important and clinically useful information regarding the
presence, etiology, and severity of myocardial injury. Fo-
cused protocols that assess ventricular morphology and
function, as well as myocardial tissue characterization,
are recommended. Special attention should be paid to
protect healthcare workers and patients from exposure
risks with the appropriate use of PPE during the visit
and additional time allocated to disinfect between
exams. The prognostic value of CMR, and as an imaging
biomarker in this patient group, is an area of active
investigation.
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